Angiotensin II receptor antagonists - antihypertensive agents

Bibliography

• KLEINERT HD: Recent developments in renin inhibitors.
   Google Scholar
• ••Exp. Opin. Invest. Drugs (1994) 3(11):1087–1104. A detailed discussion of the development of renin inhibitors.
   Google Scholar
• WEXLER RR, GREENLEE WJ, IRVIN JD et al.: Non-peptide angiotensin II receptor antagonists: the next genera-tion in antihypertensive therapy. J Med. Chem. (1996) 39(3):625–656. An outstanding review of the molecules developed as angiotensin II receptor antagonists.
   Google Scholar
• BUMPUS FM, CATT KJ, CHIU AT et al.: Nomenclature for angiotensin receptors. Hypertension (1991) 17:720–721.
   PubMed Web of Science ®Google Scholar
• SMITH RD, TIMMERMANS PBMWM: Human angiotensin receptor subtypes. CUIT. Opin. Nephrol. Hypertens. (1994) 3:112–122.
   PubMedGoogle Scholar
• BERGSMA DJ, ELLIS C, KUMAR C et al.: Cloning andcharacterization of a human angiotensin II Type 1 receptor. Biochem. Biophys. Res. Commun. (1992) 183:989–995.
   PubMed Web of Science ®Google Scholar
• KAMBAYASHI Y, BARDHAN S, TAKAHASHI K et al.: Mo-lecular cloning of a novel angiotensin II receptor iso-form involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. (1993) 268:24543–24546.
   PubMed Web of Science ®Google Scholar
• MUKOYAMA M, NAKAJIMA M, HORIUCHI M eta].: Expres-sion cloning of Type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. Biol. Chem. (1993) 268:24539–24542.
   Google Scholar
• BOTTARI SP, KING IN, REICHLIN S eta].: The angiotensinAT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guany-late cyclase. Biochem. Biophys. Res. Commun. (1992) 183( 0:206–211.
   Google Scholar
• LO M, LIU K, LANTELM P, SASSARD J: Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Gin. Invest. (1995) 95:1394-1397. This paper suggests for the first time that AT2 receptors contribute to the regulation of sodium excretion in the rat.
   Google Scholar
• NAKAJIMA M, HUTCHINSON HG, FUJINAGA M et al.: Theangiotensin II Type 2 (AT2) receptor antagonizes the growth effect of the ATi receptor: gain-of-function study using gene transfer. Proc. Natl. Acad. Sci. USA (1995) 92:10663–10667.
   PubMed Web of Science ®Google Scholar
• STOLL M, STECKELINGS M, PAUL M eta].: The angiotensinAT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. (1995) 95:651–657.
   Google Scholar
• LEVY BI, BENESSIANO J, HENRION D et al.: Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J. Clin. Invest. (1996) 98:418-425. This study suggests that AT2, but not ATI receptors are involved in vascular hypertrophy in the rat.
   Google Scholar
• BRILLA CG, ZHOU G, MATSUBARA L, WEBER KL: Collagenmetabolism in cultured adult rat cardiac fibroblast response to angiotensin II and aldosterone../ Mol Cardiol. (1994) 26:809–820.
   PubMed Web of Science ®Google Scholar
• TIMMERMANS PBMWM, WONG PC, CHIU AT et al.:
   Google Scholar
• ••Angiotensin II receptors and angiotensin II receptorantagonists. Pharmacol. Rev. (1993) 45(2):205–251. An important review on the physiology and pharmacology of angiotensin II receptors and receptor antagonists.
   Google Scholar
• LAFAYETTE RA, MAYER G, PARK SK, MEYER TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J. Clin. Invest (1992) 90:766–771.
   PubMed Web of Science ®Google Scholar
• VON LUTTEROTI N, CAMARGO MJF, CAMPBELL WG et al.:Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl-sensitive rats. J. Hypertens. (1992) 10:949–957.
   PubMed Web of Science ®Google Scholar
• FORNES P, RICHER C, VACHER E, BRUNEVAL P, GI-UDICELLI JF. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after withdrawal. J. Cardiovasc. Pharmacol (1993) 22:305–313.
   Google Scholar
• GRADHAM AH, ARCURI KE, GOLDBERG Al et al.: A ran-domised, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with e nal april male ate in patients with essential hyper-tension. Hypertension (1995) 25:1345–1350.
   PubMed Web of Science ®Google Scholar
• GOLDBERG A, DUNLAY M, SWEET C: The safety and tolerability of losartan potassium, an angiotensin II receptor antagonist in comparison with hydrochlo-rothiazide, atenolol, felodipine ER and ACE-inhibitors for the treatment of systemic hypertension. Am. J. Cardiol. (1995) 75(12):793–795.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, KELLER SE, MAKRIS L et al. Efficacy and tolerability of losartan potassium and atenolol in pa- tients with mild to moderate essential hypertension. Am. J. Hypertens. (1995) 8:578–583.
   PubMed Web of Science ®Google Scholar
• LACOURCIERE Y, BRUNNER H, IRWIN R eta].: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J. Hypertens. (1994) 12:1387-1393. The first study demonstrating clearly the lack of cough with ATI receptor antagonists.
   Google Scholar
• DAHLOF B: Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. J. Human Hy-pertens. (1995) 9\(Suppl. 5):S37–S44.
   Google Scholar
• GOTTLIEB SS, DICKSTEIN K, FLECK E etal: Hemodynamic and neurohormonal effects of the angiotensin II an-tagonist losartan in patients with congestive heart fail-ure. Circulation (1993) 8\(Part 0:1602–1609.
   Google Scholar
• CROZIER I, IKRAM H, AWAN N et al.: Losartan in heart failure. Hemodynamic effects and tolerability. Circula-tion (1995) 91:691–697
   PubMed Web of Science ®Google Scholar
• DICKSTEINK, CHANG P, WILLENHEIMER R eta].: Compari-son of the effects of losartan and enalapril on clinical status and exercise performance in patients with mod-erate or severe chronic heart failure .J. Am. Coll. Cardiol (1995) 26:438–445.
   Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• GANSEVOORT RT, DE ZEEUW D, DE JONG PE: Is the antiproteinuric effect of ACE inhibition mediated byinterference in the renin-angiotensin system? Kidney Int. (1994) 45:861-867. First study comparing clinically the renal effect of an ACE inhibitor and an ATI receptor antagonist.
   Google Scholar
• CHAN JCN, CRITCHLEY JAJH, TOMLINSON B, CHAN TYK, COCKRAM CS: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-in-sulin-dependent diabetes mellitus. Am. J. Nephrol (1997) 17(1)72–80.
   Google Scholar
• ACKER CG, GREENBERG A: Angioedema induced by the angiotensin II blocker losartan. New Engl. J. Merl. (1995) 333:1572.
   PubMed Web of Science ®Google Scholar
• BURNIER M, RUTSCHMANN B, NUSSBERGER J et al.: Salt- dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension (1993) 22:339-347. First suggestion that the uricosuric effect of losartan is due to the parent compound and not its metabolite.
   Google Scholar
• BURNIER M, WAEBER B, BRUNNER HR: The advantagesof angiotensin II antagonism. J. Hypertens. (1994) 12 (Suppl. 2):57–515.
   Google Scholar
• SOFFER BA, WRIGHT JT, PRATT JH et aL: Effects oflosartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension (1995) 26:112–117.
   PubMed Web of Science ®Google Scholar
• CANNON PJ, STASON WB, DEMARTININ FE, SOMMERS SC,LARAGH JH: Hyperuricaemia in primary and renal hy-pertension. New Engl. J. Med (1966) 275:457–464.
   PubMed Web of Science ®Google Scholar
• CRISCIONE L, DE GASPARO M, BUHLMAYER P et al Pharmacological profile of valsartan: a potent, orally active, non-peptide antagonist of the angiotensin II ATi-receptor subtype. Br. J. Pharmacol. (1993) 110:761–771.
   PubMed Web of Science ®Google Scholar
• BUHLMAYER P, FURET P, CRISCIONE Let al.: Valsartan, a potent, orally active angiotensin II antagonist devel-oped from the structurally new amino acid series. Bioorg. Med. Chem. Lett. (1994) 4:29–34.
   Google Scholar
• MULLER P, COHEN T, DE GASPARO M eta]: Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur. j Clin. Pharmacol (1994) 47:231–245.
   PubMed Web of Science ®Google Scholar
• HOLWERDA NJ, FOGARI R, ANGELI P eta].:Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension - efficacy and safety compared with placebo and enalapril. J. Hypertens. (19 9 6) 14(9):1147–1151.
   Google Scholar
• COREA L, CARDONI 0, FOGARI R eta].: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin. Pharmacol Ther. (1996) 60:341–346.
   Google Scholar
• CAZAUBON C, GOUGAT J, BOUSQUET F et al: Pharma-cological characterisation of SR 47436, a new non-pep-tide AT1 subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. (1993) 265:826–834.
   PubMed Web of Science ®Google Scholar
• ROCCON A, MARCHIONNI D, DONAT ? et al.: A pharma-codynamic study of SR 47436, a selective ATi receptor antagonist, on blood pressure in conscious cyno-mologus monkeys. Br. J. Pharmacol (1994) 111:145–150.
   Google Scholar
• CHRISTOPHE B, LIBON R, CAZAUBON C eta].: Effects ofirbesartan (5R47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat - potential mechanism of action. Eur. J. Pharmacol. (1995) 281 (2) :161–171.
   Google Scholar
• RIBSTEIN J, SISSMANN J, PICARD A, BOUROUDIAN M,MIMRAN A: Effect of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exoge-nous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. j Hypertens. (1994) 12\(Suppl. 3):131.
   Google Scholar
• BURNIER M, HAGMAN M, NUSSBERGER J eta].: Short-termand sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension (1995) 2 5\(Part 0602–609.
   Google Scholar
• MCINTYRE M, MACFAYDEN RJ, MEREDITH PA, BROUARDR, REID JL: Dose ranging study of the ATi antagonist irbesartan (SR-47436/BMS-186295) on blood pressure and neurohormonal effects in salt depleted men. J. Cardiovasc. Pharmacol. (1996) 28(1):101–106.
   PubMed Web of Science ®Google Scholar
• VAN DEN MEIRACKER AH, ADMIRAAL PJJ, JANSSEN JA etal.: Hemodynamic and biochemical effects of the ATi receptor antagonist irbesartan in hypertension. Hyper-tension (1995) 25:22–29.
   Web of Science ®Google Scholar
• SHIBOUTA Y, INADA Y, OJIMA M eta].: Pharmacologicalprofile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[(2'-(1H- tetrazol-5-y0 bip henyl-4-ylimet hyl] -1H -benzimidazole -7-carbox-ylic acid (CV- 11974), and its prodrug, (±)-1-(cyclohexy-loxy-carbonyloxy) -ethyl-2-ethoxy-1-[(2'-(1H-tetrazol-5y0 bip heny1-4-yl] met hyl] -1H -benzimidazole -7-carbo-xylate (TCV- 116).j Pharmacol. Exp. Ther. (1993) 266:114–120.
   Google Scholar
• INADA Y, WADA T, SHIBOUTA Y eta].: Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (±)-1- (cyclohexyloxy-carbonyl oxy)-ethyl-2-et hoxy-1-[(2'-(1H-tetrazol-5y1)-bi phenyl-4-yl] methyl] -1 H-benzimi dazole -7-carboxyl at e (TCV-116) in various hypertensive rats. J. Pharmacol Exp. Ther. (1994) 268:1540–1547.
   Google Scholar
• MIZUNO K, NIIMURA S, KATOH K, FUKUCHI S: TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats. Life Sci. (1994) 54:1987–1994.
   PubMed Web of Science ®Google Scholar
• KAWAMURA M, TERASHITA Z-I, OKUDA H eta].: TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular func-tion after carotid injury in rats. J. Pharmacol Exp. Ther. (1993) 266:1664–1669.
   Google Scholar
• DELACRÉTAZ E, NUSSBERGER J, BIOLLAZ J, WAEBER B, BRUNNER HR: Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension (1995) 25:14-21. First characterisation of the pharmacodynamic effects of candesartan in humans.
   Google Scholar
• HODGES JC: Angiotensin antagonists: agents that interact with the AT2 receptor and their potential utilities. Exp. Opin. Ther. Patents (1994) 4:1325-1338. A good review on AT2 receptor antagonists.
   Google Scholar
• BLANKLEY CJ, HODGES JC, KLUTCHKO SR eta].: Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J. Med. Chem. (1991) 34:3248–3260.
   Google Scholar
• KLUTCHKO S, HAMBY JM, HODGES JC: Tetr ahydroisoqui-noline derivatives with AT2-specific angiotensin II re-ceptor binding inhibitory activity. Bioorg. Med. Chem. Lett. (1994) 4:57–62.
   Web of Science ®Google Scholar
• GLINKA TW, DE LASZLO SE, TRAN J et al: L-161,638 apotent selective quinazolinone angiotensin II binding inhibitor. Bioorg. Med. Chem. Lett. (1994) 4:1479.
   Web of Science ®Google Scholar
• BRECHLER V, JONES PW, LEVENS NR, DEGASPARO M, BOTTARI SP: Agonistic and antagonistic properties of angiotensin analogs at the AT2 receptor in PC12W cells. Regul Pept. (1993) 44:207–213.
   PubMed Web of Science ®Google Scholar
• ZHANG J, ENTZEROTH M, WIENEN W, VANMEEL JCA: Characterization of BIBS39 and BIBS222: two new non-peptide angiotensin II receptor antagonists. Eur. J. Phar-macol (1992) 218:35–41.
   PubMed Web of Science ®Google Scholar
• SANTELLA JB, DUNCIA JV, ENSINGER CL eta].: Balanced angiotensin II receptor antagonists. M. The effects of substitution at the imidazole 5-position. Bioorg. Med. Chem. Lett (1994) 4:2235–2240.
   Google Scholar
• QUAN ML, CHIU AT, EILIS CD et al: Balanced AVAT2 receptor antagonists. IV. Orally active 5(3-amino-propanoy0imidazoles possessing equal affinity for the ATi and the AT2 receptors. J. Med. Chem. (1995) 38(15):2938–2945.
   Google Scholar
• WONG PC, QUAN ML, HAIJ-ALI AF eta].: Pharmacology of XR510, a potent orally active non-peptide angioten-sin II ATi receptor antagonist with high affinity for the AT2 receptor subtype. Cardiovasc. Pharmacol. (1995) 26(3):354–362.
   Google Scholar
• GLINKA TW, DE LASZLO SE, SIEGL PKS eta].: Developmentof balanced angiotensin II antagonists equipotent to-wards human AT1 and AT2 receptor subtypes. Bioorg Med. Chem. Lett. (1994) 4:2337–2342.
   Google Scholar
• CHRISTEN Y, WAEBER B, NUSSBERGER J et al.: Oraladministration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhi-bition of pressor response to exogenous angiotensin I and II. Circulation (1991) 83:1333–1342.
   Google Scholar
• NUSSBERGER J, WAEBER B, BRUNNER HR: Clinical phar-macology of ACE inhibition. Cardiology (1989) 76 (Suppl. 2):11–22.
   Google Scholar
• NUSSBERGER J, BRUNNER DB, WAEBER B, BRUNNER HR:True versus immunoreactive angiotensin II in human plasma. Hypertension (1985) 7 (Suppl. I):11–17.
   Google Scholar
• MOOSER V, NUSSBERGER J, JUILLERAT L et al.: Reactivehyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J. Cardiovasc. Pharmacol. (1990) 15:276–282.
   PubMed Web of Science ®Google Scholar
• NISHIMURA H, HOFFMANN S, BALTATU 0 etal: Angiotensin I converting enzyme and chymase in cardiovascular tissues. Kidney Intr. (1996) Suppl. 55:S18-S23. An excellent review on the different pathways leading to the generation of angiotensin.
   Google Scholar
• AZIZI M, CHATELLIER G, GUYENE IT et al.: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted nor-mote nsives. Circulation (1995) 92:825-834. First demonstration in normal subjects of the additive affects of an ACE inhibitor and an ATI receptor antagonist.
   Google Scholar